Drugs / Rolipram
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00369798 | Aug 2006 → Jun 2016 | major depressive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 1 | NCT00250172 | Oct 2005 → Feb 2009 | — | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02743377 | Apr 2018 → Oct 2019 | nervous system disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00011375 | Feb 2001 → Apr 2004 | multiple sclerosis | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01602900 Background | Nov 2011 → Apr 2012 | Huntington disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rolipram | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01602900 ↗ |
| Action | Inhibit | “Rolipram is a phosphodiesterase (PDE) type 4 inhibitor” NCT00011375 ↗ |
| Modality | Diagnostic / imaging agent | “As a positron emission tomography (PET) brain imaging agent, rolipram has good properties such as high affinity of 1-2 nM and appropriate lipophilicity (Log P) of \~3.” NCT00250172 ↗ |
| Route | Oral | “Patients will take Rolipram tablets in increasing doses every 2 to 3 days” NCT00011375 ↗ |